EX-2 3 frxsch13d061711ex2.txt NOTIFICATION LETTER HIGH RIVER LIMITED PARTNERSHIP c/o Icahn Associates Corp. 767 Fifth Avenue, 47th Floor New York, NY 10153 June 10, 2011 VIA HAND DELIVERY, EMAIL AND FACSIMILE -------------------------------------- Forest Laboratories, Inc. 909 Third Avenue New York, NY 10022 Attention: Corporate Secretary Re: Stockholders' Notice of Nominations of Persons for Election as Directors at the 2011 Annual Meeting of Stockholders ofForest Laboratories, Inc. (the "Corporation") ------------------------------------------------------------------------ Ladies and Gentlemen: High River Limited Partnership, a Delaware limited partnership ("High River" or the "Record Holder" hereby submits this notice (this "Notice") on the date hereof pursuant to the requirements (the "Bylaw Requirements") set forth in the Amended and Restated Bylaws of the Corporation (the "Bylaws") of its intent to nominate each person on the Slate (as defined below) for election as directors of the Corporation at the 2011 annual meeting of stockholders of the Corporation (the "Annual Meeting"), or any special meeting of stockholders of the Corporation called for a similar purpose. This Notice is submitted by the Record Holder and on behalf of the Direct Beneficial Owners and the Beneficial Owners (as defined in Annex A). As of the close of business on June 9, 2011, (i) High River represents that it is the holder of record of, and is entitled to vote, 1000 shares of Common Stock, $0.10 par value per share, of the Corporation (the "Shares") and that it is the direct beneficial owner of 3,700,121 Shares (including the 1000 Shares of which High River is the stockholder of record); (ii) Icahn Partners LP, a Delaware limited partnership ("Icahn Partners"), represents that it is the direct beneficial owner of 5,667,749 Shares and that it is not the holder of record of any Shares; (iii) Icahn Partners Master Fund LP, a Cayman Islands exempted limited partnership ("Icahn Master"), represents that it is the direct beneficial owner of 6,121,148 Shares and that it is not the holder of record of any Shares; (iv) Icahn Partners Master Fund II L.P., a Cayman Islands exempted limited partnership ("Icahn Master II"), represents that it is the direct beneficial owner of 2,098,516 Shares and that it is not the holder of record of any Shares; (v) Icahn Partners Master Fund III L.P., a Cayman Islands exempted limited partnership ("Icahn Master III" and collectively with High River, Icahn Partners, Icahn Master and Icahn Master III, the "Direct Beneficial Owners"), represents that it is the direct beneficial owner of 913,072 Shares and that it is not the holder of record of any Shares; in each case as further described in Annex A. Carl C. Icahn, by virtue of his relationship to High River, Icahn Partners, Icahn Master, Icahn Master II and Icahn Master III is deemed to beneficially own (as that term is defined in Rule 13d-3 of the Securities Act of 1933, as amended) the Shares which High River, Icahn Partners, Icahn Master, Icahn Master II and Icahn Master III directly beneficially own, as further described in Annex A. The address of Icahn Partners is 767 Fifth Avenue, 47th Floor, New York, NY 10153. The address of Icahn Master is c/o Walkers SPV Limited, P.O. Box 908GT, 87 Mary Street, George Town, Grand Cayman, Cayman Islands. The address of Icahn Master II is c/o Walkers SPV Limited, Walker House, 87 Mary Street, George Town, Grand Cayman KY1-9002, Cayman Islands. The address of Icahn Master III is c/o Walkers SPV Limited, Walker House, 87 Mary Street, George Town, Grand Cayman KY1-9002, Cayman Islands. The address of High River is 767 Fifth Avenue, 47th Floor, New York, NY 10153. Each of Icahn Master, Icahn Master II, Icahn Master III, Icahn Partners and High River is primarily engaged in the business of investing in securities. High River believes that its name and address set forth above is the name and address for the Record Holder that appears on the Corporation's books. The Record Holder hereby represents that it intends to appear in person or by proxy at the Annual Meeting to nominate for election as directors of the Corporation the following persons (each, a "Nominee" and collectively, the "Slate"): Dr. Alexander J. Denner Dr. Richard Mulligan Professor Lucian A. Bebchuk Dr. Eric J. Ende Dr. Denner has an accomplished record in improving the operations, research and development of biotech companies. Dr. Mulligan is an internationally known expert in genetics and gene therapy. Professor Bebchuk is a Professor of Law, Economics, and Finance and Director of the Program on Corporate Governance at Harvard Law School. He is one of the nation's leading corporate governance experts. Dr. Ende is a successful analyst and consultant with extensive financial expertise and a strong understanding of the pharmaceutical industry. The Record Holder believes that these experts' knowledge of science, medicine, corporate governance, finance and business will significantly improve the science, corporate governance and business expertise of the Board of Directors of the Corporation. The Record Holder also believes that each nominee is a strong stockholder-oriented individual who will help represent the best interests of the Corporation's stockholders. In this Notice: (i) certain information relating to the Direct Beneficial Owners and the Beneficial Owner(s) (as defined in Annex A) is set forth in the body of this Notice and Annex A and Annex B; (ii) certain information relating to each Nominee is set forth in the body of this Notice and Annex B; and (iii) (A) the written consent of each Nominee both to the disclosure of certain information relating to such Nominee in any applicable solicitation made by the Corporation (as required by the Bylaws) and to being named in the proxy statement as a nominee and to serve as a director if elected and (B) a statement from each Nominee that, if elected, such Nominee intends to tender, promptly following such Nominee's election or reelection, an irrevocable resignation effective upon such Nominee's failure to receive the required vote for reelection at the next meeting at which such Nominee would face reelection and upon acceptance of such resignation by the board of directors of the Corporation, in accordance with the Corporation's Board Practice on Director Elections, is attached as Annex C. Each Nominee (other than Dr. Denner) is also party to an agreement substantially in the form attached hereto as Annex D, pursuant to which Icahn Capital LP, an affiliate of the Record Holder, has agreed to pay certain fees to such Nominee and to indemnify such Nominee with respect to certain costs incurred by such Nominee in connection with the proxy contest relating to the Annual Meeting (the "Nominee Agreement"). Each Nominee, Direct Beneficial Owner and Beneficial Owner has an interest in the election of directors at the Annual Meeting: (i) directly and/or indirectly through the beneficial ownership (if any) of Shares, as described on Annex A and any applicable attachments thereto, (ii) pursuant to the Nominee Agreement, if applicable, relating to such Nominee and Icahn Capital LP, and (iii) with respect to Dr. Denner, through his profit interests in the Shares held by the Direct Beneficial Owners and their affiliates as described below. With respect to each Nominee, other than as disclosed in this Notice, (i) such Nominee is not, and, within the past year, was not a party to any contract, arrangement or understanding with any person with respect to any securities of the Corporation, including, but not limited to, joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies; and (ii) neither such Nominee nor any of such Nominee's associates have any arrangement or understanding with any person with respect to (A) any future employment by the Corporation or its affiliates or (B) any future transactions to which the Corporation or any of its affiliates will or may be a party. With respect to each Nominee, such Nominee is independent under the independence standards applicable to the Corporation under (i) paragraph (a)(1) of Item 407 of Regulation S-K and (ii) the New York Stock Exchange listing standards. In connection with his employment by Mr. Icahn and his affiliated companies, Dr. Denner, among other employees, had a participatory interest in, among other things, the profits and fees derived by Mr. Icahn and/or his affiliates from Icahn Partners', Icahn Master's, Icahn Master II's and Icahn Master III's (collectively, the "Funds") ownership of the Shares. In the aggregate, Dr. Denner's profit interests and capital accounts in the Funds entitled him to less than 2% of the profits generated by the Funds' ownership of the Shares. The foregoing with respect to the Shares has been superseded by the following as of the date of this Notice: Dr. Denner has a participatory interest in the profits attributable to the Shares beneficially owned by the Direct Beneficial Owners and their affiliates equal to 5% of an amount equal to (x) such profits minus (y) an amount equal to a return on the Direct Beneficial Owners' and their affiliates' investment in the Shares of 8% per annum, compounded annually. The Annexes and all attachments thereto are hereby incorporated into and made a part of this Notice. Accordingly, all matters disclosed in any part of this Notice, including the Annexes and all attachments thereto should be deemed disclosed for all purposes of this Notice. All upper case terms appearing in the Annexes and all attachments thereto that are not defined in such Annexes and attachments shall have the meanings given in the body of this Notice or the Annexes, as applicable. Except as to information regarding Dr. Denner's participatory interest in the profits attributable to the Shares (which is as of the close of business on June 10, 2011), information is set forth herein as of the close of business on June 9, 2011. Neither the delivery of this Notice nor any delivery by any Direct Beneficial Owner, Beneficial Owner, or Nominee of additional information to the Corporation from and after the date hereof shall be deemed to constitute an admission by any Direct Beneficial Owner, Beneficial Owner, Nominee or any of their respective affiliates (if any) that such delivery is required or that each and every item or any item of information is required or as to the legality or enforceability of any notice requirement or any other matter, or a waiver by any Direct Beneficial Owner, Beneficial Owner, Nominee or any of their respective affiliates (if any) of their right to contest or challenge, in any way, the validity or enforceability of any notice requirement or any other matter (including actions taken by the Board of Directors of the Corporation in anticipation of, or following receipt of, this Notice). Furthermore, this Notice assumes that the Board of Directors will nominate a total of nine director nominees for election to the Board of Directors at the Annual Meeting and if the Board of Directors of the Corporation increases the number of directors to be nominated and elected at the Annual Meeting or a special meeting called for a similar purpose, the Record Holder reserves the right to add additional director nominees in respect of each such additional directorship. In the event any statement or other information in this Notice is not correct, or to the extent any applicable information has been omitted from this Notice, the Direct Beneficial Owners, Beneficial Owners and Nominees reserve the right to correct and/or supplement any such statement or other information set forth in this Notice. [Signature page follows] Very truly yours, HIGH RIVER LIMITED PARTNERSHIP By: Hopper Investments LLC, its general partner By: Barberry Corp., its sole member By: /s/ Edward E. Mattner ------------------------------ Name: Edward E. Mattner Title: Authorized Signatory [Signature page to Stockholders' Notice of Nominations of Persons for Election as Directors at the 2011 Annual Meeting of Stockholders of Forest Laboratories, Inc.] ANNEX A SECURITY OWNERSHIP OF DIRECT BENEFICIAL OWNERS (1) TITLE (2) NAME OF (3) AMOUNT OF (4) PERCENT OF BENEFICIAL BENEFICIAL OF CLASS OWNER (1) OWNERSHIP (2) CLASS (3) ----- ---------- ---------- ------- Common Stock, High River 3,700,121 1.29% par value $0.01 per share ("Shares") Shares Icahn Partners 5,667,749 1.98% Shares Icahn Master 6,121,148 2.14% Shares Icahn Master II 2,098,516 0.73% Shares Icahn Master III 913,072 0.32% _________________________ (1) Please note that each stockholder listed in this table is, as of June 9, 2010, the direct beneficial owner of the Shares set forth under the heading "(3) Amount of Beneficial Ownership" and that indirect beneficial ownership of Shares is described below in the text of this Annex A under the heading "Description of Beneficial Ownership." (2) Includes Shares underlying call options as described in Attachment 1-A to this Annex A. (3) Please note that percentages of ownership set forth in this column were calculated based on the 286,162,661 Shares stated to be outstanding as of May 25, 2011 by the Corporation in the Corporation's Form 10K filed for the fiscal year ended March 31, 2011. DESCRIPTION OF BENEFICIAL OWNERSHIP AND BENEFICIAL OWNERS Barberry Corp., a Delaware corporation ("Barberry"), is the sole member of Hopper Investments LLC, a Delaware limited liability company ("Hopper"), which is the general partner of High River. Beckton Corp., a Delaware corporation ("Beckton") is the sole stockholder of Icahn Enterprises G.P. Inc., a Delaware corporation ("Icahn Enterprises GP"), which is the general partner of Icahn Enterprises Holdings L.P., a Delaware limited partnership ("Icahn Holdings"). Icahn Holdings is the sole member of IPH GP LLC, a Delaware limited liability company ("IPH"), which is the general partner of Icahn Capital L.P., a Delaware limited partnership ("Icahn Capital"). Icahn Capital is the general partner of each of Icahn Onshore LP, a Delaware limited partnership ("Icahn Onshore") and Icahn Offshore LP, a Delaware limited partnership ("Icahn Offshore"). Icahn Onshore is the general partner of Icahn Partners. Icahn Offshore is the general partner of each of Icahn Master, Icahn Master II and Icahn Master III. Each of Barberry and Beckton is 100 percent owned by Carl C. Icahn ("Mr. Icahn," and collectively with Barberry, Hopper, Beckton, Icahn Enterprises GP, Icahn Holdings, IPH, Icahn Capital, Icahn Onshore and Icahn Offshore, the "Beneficial Owners" and each of them a "Beneficial Owner." As such, Mr. Icahn is in a position indirectly to determine the investment and voting decisions made by each of the Direct Beneficial Owners. The principal business address of each of (i) Icahn Offshore, Icahn Onshore, Icahn Capital, IPH, Icahn Holdings, Icahn Enterprises GP and Beckton is White Plains Plaza, 445 Hamilton Avenue - Suite 1210, White Plains, NY 10601 and (ii) Mr. Icahn, Barberry and Hopper is c/o Icahn Capital LP, 767 Fifth Avenue, 47th Floor, New York, NY 10153. Barberry is primarily engaged in the business of serving as the sole member of Hopper and investing in securities. Hopper is primarily engaged in the business of serving as the general partner of High River and investing in securities. Icahn Offshore is primarily engaged in the business of serving as the general partner of each of Icahn Master, Icahn Master II and Icahn Master III. Icahn Onshore is primarily engaged in the business of serving as the general partner of Icahn Partners. Icahn Capital is primarily engaged in the business of serving as the general partner of each of Icahn Offshore and Icahn Onshore. IPH is primarily engaged in the business of serving as the general partner of Icahn Capital. Icahn Holdings is primarily engaged in the business of holding direct or indirect interests in various operating businesses. Icahn Enterprises GP is primarily engaged in the business of serving as the general partner of each of Icahn Enterprises and Icahn Holdings. Beckton is primarily engaged in the business of holding the capital stock of Icahn Enterprises GP. Mr. Carl C. Icahn is primarily engaged in serving as (i) Chief Executive Officer of Icahn Capital LP, a wholly owned subsidiary of Icahn Enterprises, through which Mr. Icahn manages various private investment funds, including Icahn Partners, Icahn Master, Icahn Master II and Icahn Master III, (ii) Chairman of the Board of Icahn Enterprises GP, the general partner of Icahn Enterprises L.P., a New York Stock Exchange listed diversified holding company engaged in a variety of businesses, including investment management, automotive, gaming, railcar, food packaging, metals, real estate and home fashion, and (iii) Chairman of the Board and a director of Starfire Holding Corporation ("Starfire"), a holding company engaged in the business of investing in and/or holding securities of various entities, and as Chairman of the Board and a director of various of Starfire's subsidiaries. The Direct Beneficial Owners and the Beneficial Owners may be deemed to beneficially own, in the aggregate, 18,500,606 Shares, representing approximately 6.47% of the Corporation's outstanding Shares (based upon the 286,162,661 Shares stated to be outstanding as of May 25, 2011 by the Corporation in the Corporation's Form 10K filed for the fiscal year ended March 31, 2011). High River has sole voting power and/or sole dispositive power with regard to 3,700,121 Shares (including 3,287,028 Shares underlying call options). Each of Hopper, Barberry and Mr. Icahn has shared voting power and/or shared dispositive power with regard to such Shares. Icahn Partners has sole voting power and/or sole dispositive power with regard to 5,667,749 Shares (including 5,033,797 Shares underlying call options). Each of Icahn Onshore, Icahn Capital, IPH, Icahn Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn has shared voting power and/or shared dispositive power with regard to such Shares. Icahn Master has sole voting power and/or sole dispositive power with regard to 6,121,148 Shares (including 5,424,590 Shares underlying call options). Each of Icahn Offshore, Icahn Capital, IPH, Icahn Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn has shared voting power and/or shared dispositive power with regard to such Shares. Icahn Master II has sole voting power and/or sole dispositive power with regard to 2,098,516 Shares (including 1,881,878 Shares underlying call options). Each of Icahn Offshore, Icahn Capital, IPH, Icahn Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn has shared voting power and/or shared dispositive power with regard to such Shares. Icahn Master III has sole voting power and/or sole dispositive power with regard to 913,072 Shares (including 807,848 Shares underlying call options). Each of Icahn Offshore, Icahn Capital, IPH, Icahn Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn has shared voting power and/or shared dispositive power with regard to such Shares. As described in this Notice, the Shares beneficially owned by the Direct Beneficial Owners and the Beneficial Owners include Shares underlying call options. The agreements governing these call options do not give the Direct Beneficial Owners or the Beneficial Owners direct or indirect voting, investment or dispositive control over the Shares to which these agreements relate. Each of Hopper, Barberry and Mr. Icahn, by virtue of their relationships to High River, may be deemed to indirectly beneficially own the 3,700,121 Shares which High River directly beneficially owns. Each of Icahn Onshore, Icahn Capital, IPH, Icahn Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn, by virtue of their relationships to Icahn Partners, may be deemed to indirectly beneficially own the 5,667,749 Shares which Icahn Partners directly beneficially owns. Each of Icahn Offshore, Icahn Capital, IPH, Icahn Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn, by virtue of their relationships to Icahn Master, Icahn Master II and Icahn Master III, may be deemed to indirectly beneficially own the 9,132,736 Shares which Icahn Master, Icahn Master II and Icahn Master III directly beneficially own. Without acknowledging the following disclosure is required, on January 5, 2001, Reliance Group Holdings, Inc. ("Reliance") commenced an action in the United States District Court for the Southern District of New York against Carl C. Icahn, Icahn Associates Corp. and High River alleging that High River's tender offer for Reliance 9% senior notes violated Section 14(e) of the Exchange Act. Reliance sought a temporary restraining order and preliminary and permanent injunctive relief to prevent defendants from purchasing the notes. The Court initially imposed a temporary restraining order. Defendants then supplemented the tender offer disclosures. The Court conducted a hearing on the disclosures and other matters raised by Reliance. It then denied plaintiff's motion for a preliminary injunction and ordered dissolution of its temporary restraining order following dissemination of the supplement. Reliance took an immediate appeal to the United States Court of Appeals for the Second Circuit and sought a stay to restrain defendants from purchasing notes during the pendency of the appeal. On January 30, 2001, the Court of Appeals denied plaintiff's stay application. On January 30, Reliance also sought a further temporary restraining order from the District Court. The Court considered the matter and reimposed its original restraint until noon the next day, at which time the restraint was dissolved. The appeal was argued on March 9 and denied on March 22, 2001. TWO YEAR SUMMARY TABLE: The following table indicates the date of each purchase and sale of Shares by Mr. Icahn and his affiliates within the past two years, and the number of Shares in each such purchase and sale. NAME DATE SHARES PURCHASED ---- ---- ---------------- High River 8/21/2009 80,000 High River 8/24/2009 1,080 High River 8/25/2009 31,280 High River 8/27/2009 120 High River 8/28/2009 13,700 High River 9/1/2009 33,820 High River 9/2/2009 30,000 High River 9/11/2009 23,060 High River 9/14/2009 1,640 High River 9/15/2009 25,300 High River 9/24/2009 10,000 High River 10/2/2009 10,000 High River 10/26/2009 23,280 High River 10/28/2009 20,000 High River 3/1/2011 48,813 High River 3/1/2011 1,000 High River 3/2/2011 40,000 High River 3/4/2011 20,000 Icahn Partners 8/21/2009 109,547 Icahn Partners 8/24/2009 1,478 Icahn Partners 8/25/2009 42,834 Icahn Partners 8/27/2009 165 Icahn Partners 8/28/2009 18,759 Icahn Partners 9/1/2009 46,823 Icahn Partners 9/2/2009 41,165 Icahn Partners 9/11/2009 31,651 Icahn Partners 9/14/2009 2,250 Icahn Partners 9/15/2009 34,724 Icahn Partners 9/24/2009 13,725 Icahn Partners 10/2/2009 14,680 Icahn Partners 10/26/2009 32,053 Icahn Partners 10/28/2009 27,524 Icahn Partners 3/1/2011 115,927 Icahn Partners 3/2/2011 69,954 Icahn Partners 3/4/2011 30,693 Icahn Master 8/21/2009 134,886 Icahn Master 8/24/2009 1,820 Icahn Master 8/25/2009 52,741 Icahn Master 8/27/2009 202 Icahn Master 8/28/2009 23,099 Icahn Master 9/1/2009 57,157 Icahn Master 9/2/2009 50,571 Icahn Master 9/11/2009 38,896 Icahn Master 9/14/2009 2,765 Icahn Master 9/15/2009 42,674 Icahn Master 9/24/2009 16,867 Icahn Master 10/2/2009 18,530 Icahn Master 10/26/2009 39,409 Icahn Master 10/28/2009 33,863 Icahn Master 3/1/2011 72,491 Icahn Master 3/2/2011 76,863 Icahn Master 3/4/2011 33,724 Icahn Master II 8/21/2009 54,727 Icahn Master II 8/24/2009 739 Icahn Master II 8/25/2009 21,399 Icahn Master II 8/27/2009 81 Icahn Master II 8/28/2009 9,373 Icahn Master II 9/1/2009 22,622 Icahn Master II 9/2/2009 20,465 Icahn Master II 9/11/2009 15,704 Icahn Master II 9/14/2009 1,119 Icahn Master II 9/15/2009 17,231 Icahn Master II 9/24/2009 6,811 Icahn Master II 10/2/2009 5,113 Icahn Master II 10/26/2009 15,701 Icahn Master II 10/28/2009 13,491 Icahn Master II 3/2/2011 1,572 Icahn Master II 3/4/2011 10,490 Icahn Master III 8/21/2009 20,840 Icahn Master III 8/24/2009 283 Icahn Master III 8/25/2009 8,146 Icahn Master III 8/27/2009 32 Icahn Master III 8/28/2009 3,569 Icahn Master III 9/1/2009 8,678 Icahn Master III 9/2/2009 7,799 Icahn Master III 9/11/2009 5,989 Icahn Master III 9/14/2009 426 Icahn Master III 9/15/2009 6,571 Icahn Master III 9/24/2009 2,597 Icahn Master III 10/2/2009 1,677 Icahn Master III 10/26/2009 5,957 Icahn Master III 10/28/2009 5,122 Icahn Master III 3/1/2011 10,834 Icahn Master III 3/2/2011 11,611 Icahn Master III 3/4/2011 5,093 Shares purchased by each of the Record Holders are maintained in margin accounts that include positions in securities in addition to the Shares. As of June 9, 2011, the indebtedness of (i) High River's margin account was approximately $247,012,854, (ii) Icahn Partners' margin account was approximately $429,275,023, (iii) Icahn Master's margin account was approximately $426,974,384, (iv) Icahn Master II's margin account was approximately $102,448,135, and (v) Icahn Master III's margin account was approximately $55,296,050. ANNEX A ATTACHMENT 1-A The following are American call options purchased by the Direct Beneficial Owners, which have been written by UBS AG with a $21.25 strike price and an expiration date of March 7, 2013, and which provide for physical settlement (unless the applicable the Direct Beneficial Owner opts for a cash settlement). These are further described in the chart set forth below. NAME DATE QUANTITY OPTION PREMIUM PAID ($) ---- ---- -------- ----------------------- High River 3/7/2011 40,000 439,412.00 High River 3/8/2011 24,958 278,134.45 High River 3/10/2011 25,688 279,305.62 High River 3/11/2011 20,000 211,742.00 High River 3/14/2011 26,590 275,504.31 High River 3/16/2011 67,290 616,336.03 High River 3/17/2011 40,000 375,088.00 High River 3/18/2011 40,740 389,380.70 High River 3/23/2011 4,879 46,285.61 High River 4/26/2011 66,354 772,778.59 High River 4/27/2011 30,488 361,569.39 High River 4/28/2011 320 3,801.60 High River 4/29/2011 65,980 789,127.40 High River 5/12/2011 127,227 1,574,853.97 High River 5/13/2011 101,298 1,315,921.80 High River 5/16/2011 1,329 17,220.52 High River 5/17/2011 24,003 311,628.55 High River 5/18/2011 175,365 2,393,451.67 High River 5/19/2011 222,287 3,103,904.52 High River 5/20/2011 222,384 3,128,609.30 High River 5/23/2011 155,759 2,109,428.56 High River 5/24/2011 87,833 1,203,619.52 High River 5/25/2011 162,407 2,265,528.93 High River 5/26/2011 112,860 1,596,867.43 High River 6/1/2011 12,394 176,817.76 High River 6/2/2011 42,836 610,841.36 High River 6/3/2011 446,401 6,917,340.62 High River 6/6/2011 95,000 1,454,250.50 High River 6/7/2011 262,741 4,106,247.72 High River 6/8/2011 219,098 3,452,173.82 High River 6/9/2011 362,519 5,967,389.01 Icahn Partners 3/7/2011 61,386 674,343.63 Icahn Partners 3/8/2011 38,302 426,841.32 Icahn Partners 3/10/2011 39,422 428,635.41 Icahn Partners 3/11/2011 30,692 324,939.27 Icahn Partners 3/14/2011 40,807 422,809.49 Icahn Partners 3/16/2011 103,267 945,863.76 Icahn Partners 3/17/2011 61,383 575,600.67 Icahn Partners 3/18/2011 62,522 597,566.52 Icahn Partners 3/23/2011 7,488 71,036.41 Icahn Partners 4/26/2011 103,149 1,201,304.20 Icahn Partners 4/27/2011 46,839 555,482.44 Icahn Partners 4/28/2011 493 5,856.84 Icahn Partners 4/29/2011 101,370 1,212,395.34 Icahn Partners 5/12/2011 191,068 2,365,097.02 Icahn Partners 5/13/2011 155,182 2,015,907.29 Icahn Partners 5/16/2011 2,035 26,368.51 Icahn Partners 5/17/2011 36,771 477,394.22 Icahn Partners 5/18/2011 268,648 3,666,615.36 Icahn Partners 5/19/2011 340,528 4,754,962.73 Icahn Partners 5/20/2011 340,677 4,792,814.37 Icahn Partners 5/23/2011 238,613 3,231,512.00 Icahn Partners 5/24/2011 134,553 1,843,847.04 Icahn Partners 5/25/2011 248,797 3,470,643.51 Icahn Partners 5/26/2011 172,894 2,446,294.50 Icahn Partners 6/1/2011 18,626 265,725.97 Icahn Partners 6/2/2011 65,615 935,669.90 Icahn Partners 6/3/2011 683,786 10,595,811.10 Icahn Partners 6/6/2011 145,518 2,227,574.99 Icahn Partners 6/7/2011 402,460 6,289,846.11 Icahn Partners 6/8/2011 335,608 5,287,940.33 Icahn Partners 6/9/2011 555,298 9,140,704.85 Icahn Master 3/7/2011 67,448 740,936.51 Icahn Master 3/8/2011 42,085 468,999.45 Icahn Master 3/10/2011 43,314 470,953.12 Icahn Master 3/11/2011 33,725 357,049.95 Icahn Master 3/14/2011 44,835 464,544.40 Icahn Master 3/16/2011 113,464 1,039,262.16 Icahn Master 3/17/2011 67,449 632,482.76 Icahn Master 3/18/2011 68,695 656,566.20 Icahn Master 3/23/2011 8,229 78,066.05 Icahn Master 4/26/2011 78,757 917,227.65 Icahn Master 4/27/2011 50,095 594,096.64 Icahn Master 4/28/2011 526 6,248.88 Icahn Master 4/29/2011 108,417 1,296,678.16 Icahn Master 5/12/2011 219,672 2,719,165.92 Icahn Master 5/13/2011 167,531 2,176,328.21 Icahn Master 5/16/2011 2,197 28,467.63 Icahn Master 5/17/2011 39,698 515,395.16 Icahn Master 5/18/2011 290,025 3,958,377.21 Icahn Master 5/19/2011 367,627 5,133,359.61 Icahn Master 5/20/2011 367,787 5,174,211.41 Icahn Master 5/23/2011 257,602 3,488,678.13 Icahn Master 5/24/2011 145,261 1,990,584.11 Icahn Master 5/25/2011 268,594 3,746,805.72 Icahn Master 5/26/2011 186,653 2,640,971.96 Icahn Master 6/1/2011 21,565 307,654.92 Icahn Master 6/2/2011 70,863 1,010,506.38 Icahn Master 6/3/2011 738,386 11,443,431.36 Icahn Master 6/6/2011 157,160 2,405,789.56 Icahn Master 6/7/2011 434,655 6,793,005.67 Icahn Master 6/8/2011 362,455 5,710,949.72 Icahn Master 6/9/2011 599,720 9,871,930.95 Icahn Master II 3/7/2011 20,976 230,427.65 Icahn Master II 3/8/2011 13,089 145,865.12 Icahn Master II 3/10/2011 13,472 146,481.06 Icahn Master II 3/11/2011 10,488 111,037.50 Icahn Master II 3/14/2011 13,945 144,486.93 Icahn Master II 3/16/2011 35,288 323,216.91 Icahn Master II 3/17/2011 20,979 196,724.28 Icahn Master II 3/18/2011 21,365 204,200.26 Icahn Master II 3/23/2011 2,558 24,266.98 Icahn Master II 4/26/2011 71,564 833,455.81 Icahn Master II 4/27/2011 17,447 206,910.95 Icahn Master II 4/28/2011 182 2,162.16 Icahn Master II 4/29/2011 37,753 451,529.66 Icahn Master II 5/12/2011 68,223 844,484.76 Icahn Master II 5/13/2011 57,497 746,920.53 Icahn Master II 5/16/2011 755 9,782.91 Icahn Master II 5/17/2011 13,624 176,879.03 Icahn Master II 5/18/2011 99,536 1,358,507.14 Icahn Master II 5/19/2011 126,170 1,761,774.80 Icahn Master II 5/20/2011 126,226 1,775,810.48 Icahn Master II 5/23/2011 88,408 1,197,300.70 Icahn Master II 5/24/2011 49,853 683,160.59 Icahn Master II 5/25/2011 92,180 1,285,883.35 Icahn Master II 5/26/2011 64,059 906,377.20 Icahn Master II 6/1/2011 6,014 85,798.13 Icahn Master II 6/2/2011 24,296 346,460.96 Icahn Master II 6/3/2011 253,176 3,923,164.66 Icahn Master II 6/6/2011 53,880 824,789.65 Icahn Master II 6/7/2011 149,013 2,328,849.67 Icahn Master II 6/8/2011 124,261 1,957,893.59 Icahn Master II 6/9/2011 205,601 3,384,377.50 Icahn Master III 3/7/2011 10,190 111,940.21 Icahn Master III 3/8/2011 6,357 70,843.04 Icahn Master III 3/10/2011 6,543 71,142.04 Icahn Master III 3/11/2011 5,095 53,941.27 Icahn Master III 3/14/2011 6,773 70,176.41 Icahn Master III 3/16/2011 17,141 157,001.28 Icahn Master III 3/17/2011 10,189 95,544.29 Icahn Master III 3/18/2011 10,378 99,189.81 Icahn Master III 3/23/2011 1,243 11,791.97 Icahn Master III 4/26/2011 11,944 139,103.41 Icahn Master III 4/27/2011 7,569 89,763.80 Icahn Master III 4/28/2011 79 938.52 Icahn Master III 4/29/2011 16,382 195,930.36 Icahn Master III 5/12/2011 29,945 370,668.19 Icahn Master III 5/13/2011 24,984 324,557.15 Icahn Master III 5/16/2011 327 4,237.10 Icahn Master III 5/17/2011 5,921 76,871.75 Icahn Master III 5/18/2011 43,250 590,293.30 Icahn Master III 5/19/2011 54,822 765,507.00 Icahn Master III 5/20/2011 54,846 771,600.95 Icahn Master III 5/23/2011 38,415 520,250.50 Icahn Master III 5/24/2011 21,663 296,858.92 Icahn Master III 5/25/2011 40,055 558,755.23 Icahn Master III 5/26/2011 27,833 393,811.90 Icahn Master III 6/1/2011 3,373 48,120.57 Icahn Master III 6/2/2011 10,570 150,728.20 Icahn Master III 6/3/2011 110,158 1,706,986.34 Icahn Master III 6/6/2011 23,442 358,847.79 Icahn Master III 6/7/2011 64,836 1,013,289.43 Icahn Master III 6/8/2011 54,066 851,880.12 Icahn Master III 6/9/2011 89,459 1,472,575.65 ANNEX A ATTACHMENT 1-B The following are European put options which have been written by the Direct Beneficial Owners to UBS AG and have a $21.25 strike price and an expiration date of the earlier of March 7, 2013 or the date on which the corresponding American-style call option described above in Annex A, Attachment 1-A is exercised, and provide for cash settlement only and are further described in the chart set forth below. NAME DATE QUANTITY OPTION PREMIUM PAID ($) ---- ---- -------- ----------------------- High River 3/7/2011 40,000 400.00 High River 3/8/2011 24,958 249.58 High River 3/10/2011 25,688 256.88 High River 3/11/2011 20,000 200.00 High River 3/14/2011 26,590 265.90 High River 3/16/2011 67,290 672.90 High River 3/17/2011 40,000 400.00 High River 3/18/2011 40,740 407.40 High River 3/23/2011 4,879 48.79 High River 4/26/2011 66,354 663.54 High River 4/27/2011 30,488 304.88 High River 4/28/2011 320 3.20 High River 4/29/2011 65,980 659.80 High River 5/12/2011 127,227 1,272.27 High River 5/13/2011 101,298 1,012.98 High River 5/16/2011 1,329 13.29 High River 5/17/2011 24,003 240.03 High River 5/18/2011 175,365 1,753.65 High River 5/19/2011 222,287 2,222.87 High River 5/20/2011 222,384 2,223.84 High River 5/23/2011 155,759 1,557.59 High River 5/24/2011 87,833 878.33 High River 5/25/2011 162,407 1,624.07 High River 5/26/2011 112,860 1,128.60 High River 6/1/2011 12,394 123.94 High River 6/2/2011 42,836 428.36 High River 6/3/2011 446,401 4,464.01 High River 6/6/2011 95,000 950.00 High River 6/7/2011 262,741 2,627.41 High River 6/8/2011 219,098 2,190.98 High River 6/9/2011 362,519 3,625.19 Icahn Partners 3/7/2011 61,386 613.86 Icahn Partners 3/8/2011 38,302 383.02 Icahn Partners 3/10/2011 39,422 394.22 Icahn Partners 3/11/2011 30,692 306.92 Icahn Partners 3/14/2011 40,807 408.07 Icahn Partners 3/16/2011 103,267 1,032.67 Icahn Partners 3/17/2011 61,383 613.83 Icahn Partners 3/18/2011 62,522 625.22 Icahn Partners 3/23/2011 7,488 74.88 Icahn Partners 4/26/2011 103,149 1,031.49 Icahn Partners 4/27/2011 46,839 468.39 Icahn Partners 4/28/2011 493 4.93 Icahn Partners 4/29/2011 101,370 1,013.70 Icahn Partners 5/12/2011 191,068 1,910.68 Icahn Partners 5/13/2011 155,182 1,551.82 Icahn Partners 5/16/2011 2,035 20.35 Icahn Partners 5/17/2011 36,771 367.71 Icahn Partners 5/18/2011 268,648 2,686.48 Icahn Partners 5/19/2011 340,528 3,405.28 Icahn Partners 5/20/2011 340,677 3,406.77 Icahn Partners 5/23/2011 238,613 2,386.13 Icahn Partners 5/24/2011 134,553 1,345.53 Icahn Partners 5/25/2011 248,797 2,487.97 Icahn Partners 5/26/2011 172,894 1,728.94 Icahn Partners 6/1/2011 18,626 186.26 Icahn Partners 6/2/2011 65,615 656.15 Icahn Partners 6/3/2011 683,786 6,837.86 Icahn Partners 6/6/2011 145,518 1,455.18 Icahn Partners 6/7/2011 402,460 4,024.60 Icahn Partners 6/8/2011 335,608 3,356.08 Icahn Partners 6/9/2011 555,298 5,552.98 Icahn Master 3/7/2011 67,448 674.48 Icahn Master 3/8/2011 42,085 420.85 Icahn Master 3/10/2011 43,314 433.14 Icahn Master 3/11/2011 33,725 337.25 Icahn Master 3/14/2011 44,835 448.35 Icahn Master 3/16/2011 113,464 1,134.64 Icahn Master 3/17/2011 67,449 674.49 Icahn Master 3/18/2011 68,695 686.95 Icahn Master 3/23/2011 8,229 82.29 Icahn Master 4/26/2011 78,757 787.57 Icahn Master 4/27/2011 50,095 500.95 Icahn Master 4/28/2011 526 5.26 Icahn Master 4/29/2011 108,417 1,084.17 Icahn Master 5/12/2011 219,672 2,196.72 Icahn Master 5/13/2011 167,531 1,675.31 Icahn Master 5/16/2011 2,197 21.97 Icahn Master 5/17/2011 39,698 396.98 Icahn Master 5/18/2011 290,025 2,900.25 Icahn Master 5/19/2011 367,627 3,676.27 Icahn Master 5/20/2011 367,787 3,677.87 Icahn Master 5/23/2011 257,602 2,576.02 Icahn Master 5/24/2011 145,261 1,452.61 Icahn Master 5/25/2011 268,594 2,685.94 Icahn Master 5/26/2011 186,653 1,866.53 Icahn Master 6/1/2011 21,565 215.65 Icahn Master 6/2/2011 70,863 708.63 Icahn Master 6/3/2011 738,386 7,384.86 Icahn Master 6/6/2011 157,160 1,571.60 Icahn Master 6/7/2011 434,655 4,346.55 Icahn Master 6/8/2011 362,455 3,624.55 Icahn Master 6/9/2011 599,720 5,997.20 Icahn Master II 3/7/2011 20,976 209.76 Icahn Master II 3/8/2011 13,089 130.89 Icahn Master II 3/10/2011 13,472 134.72 Icahn Master II 3/11/2011 10,488 104.88 Icahn Master II 3/14/2011 13,945 139.45 Icahn Master II 3/16/2011 35,288 352.88 Icahn Master II 3/17/2011 20,979 209.79 Icahn Master II 3/18/2011 21,365 213.65 Icahn Master II 3/23/2011 2,558 25.58 Icahn Master II 4/26/2011 71,564 715.64 Icahn Master II 4/27/2011 17,447 174.47 Icahn Master II 4/28/2011 182 1.82 Icahn Master II 4/29/2011 37,753 377.53 Icahn Master II 5/12/2011 68,223 682.23 Icahn Master II 5/13/2011 57,497 574.97 Icahn Master II 5/16/2011 755 7.55 Icahn Master II 5/17/2011 13,624 136.24 Icahn Master II 5/18/2011 99,536 995.36 Icahn Master II 5/19/2011 126,170 1,261.70 Icahn Master II 5/20/2011 126,226 1,262.26 Icahn Master II 5/23/2011 88,408 884.08 Icahn Master II 5/24/2011 49,853 498.53 Icahn Master II 5/25/2011 92,180 921.80 Icahn Master II 5/26/2011 64,059 640.59 Icahn Master II 6/1/2011 6,014 60.14 Icahn Master II 6/2/2011 24,296 242.96 Icahn Master II 6/3/2011 253,176 2,531.76 Icahn Master II 6/6/2011 53,880 538.80 Icahn Master II 6/7/2011 149,013 1,490.13 Icahn Master II 6/8/2011 124,261 1,242.61 Icahn Master II 6/9/2011 205,601 2,056.01 Icahn Master III 3/7/2011 10,190 101.90 Icahn Master III 3/8/2011 6,357 63.57 Icahn Master III 3/10/2011 6,543 65.43 Icahn Master III 3/11/2011 5,095 50.95 Icahn Master III 3/14/2011 6,773 67.73 Icahn Master III 3/16/2011 17,141 171.41 Icahn Master III 3/17/2011 10,189 101.89 Icahn Master III 3/18/2011 10,378 103.78 Icahn Master III 3/23/2011 1,243 12.43 Icahn Master III 4/26/2011 11,944 119.44 Icahn Master III 4/27/2011 7,569 75.69 Icahn Master III 4/28/2011 79 0.79 Icahn Master III 4/29/2011 16,382 163.82 Icahn Master III 5/12/2011 29,945 299.45 Icahn Master III 5/13/2011 24,984 249.84 Icahn Master III 5/16/2011 327 3.27 Icahn Master III 5/17/2011 5,921 59.21 Icahn Master III 5/18/2011 43,250 432.50 Icahn Master III 5/19/2011 54,822 548.22 Icahn Master III 5/20/2011 54,846 548.46 Icahn Master III 5/23/2011 38,415 384.15 Icahn Master III 5/24/2011 21,663 216.63 Icahn Master III 5/25/2011 40,055 400.55 Icahn Master III 5/26/2011 27,833 278.33 Icahn Master III 6/1/2011 3,373 33.73 Icahn Master III 6/2/2011 10,570 105.70 Icahn Master III 6/3/2011 110,158 1,101.58 Icahn Master III 6/6/2011 23,442 234.42 Icahn Master III 6/7/2011 64,836 648.36 Icahn Master III 6/8/2011 54,066 540.66 Icahn Master III 6/9/2011 89,459 894.59 ANNEX B ATTACHMENT 1 INFORMATION ABOUT NOMINEES -------------------------- NAME: Alexander J. Denner, Ph.D. AGE: 41 BUSINESS Icahn Associates Corp.,767 Fifth Avenue, 47th Floor, ADDRESS: New York, NY 10153 RESIDENCE 565 Stanwich Road ADDRESS: Greenwich, CT 06831 PRINCIPAL OCCUPATION See below OR EMPLOYMENT: CITIZENSHIP: United States of America Dr. Denner has an interest in the election of directors at the Annual Meeting indirectly through his profit interests in the Shares held by the Direct Beneficial Owners as described below. Other than in respect of such profit interests, Dr. Denner does not, and his associates do not, own, beneficially or of record, any shares of capital stock of the Corporation. Dr. Denner has a participatory interest in the profits attributable to the Shares beneficially owned by the Direct Beneficial Owners and their affiliates equal to 5% of an amount equal to (x) such profits minus (y) an amount equal to a return on the Direct Beneficial Owners' and their affiliates' investment in the Shares of 8% per annum, compounded annually. Dr. Denner's principal occupation is serving as Managing Director of entities affiliated with Carl C. Icahn, including Icahn Partners, Icahn Master, Icahn Master II and Icahn Master III (collectively, the "Funds"). The Funds are private investment funds. Dr. Denner has served in this position since August 2006. From April 2005 to May 2006, Dr. Denner served as a portfolio manager specializing in healthcare investments for Viking Global Investors. Previously, he served in a variety of roles at Morgan Stanley, beginning in 1996, including as portfolio manager of healthcare and biotechnology mutual funds. Dr. Denner was the chairman of the Executive Committee of the Board of Directors of ImClone Systems Incorporated, a publicly traded biopharmaceutical company, and a director of ImClone Systems Incorporated from April 2006 until the company was purchased in December 2008. He served on the Board of Adventrx Pharmaceuticals Inc., a publicly traded biopharmaceutical company from October 2006 to October 2009. In addition, Dr. Denner has served as a director of Biogen Idec Pharmaceuticals, a publicly traded biopharmaceutical company from June, 2009 until the present, as a director of Amylin Pharmaceuticals, Inc., a publicly traded biopharmaceutical company from June 2009 until the present, and as a director of Enzon Pharmaceuticals, a publicly traded biopharmaceutical company from May 2009 until the present, and as Chairman of the Board of Directors of Enzon Pharmaceuticals from July, 2009 until the present. Dr. Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil., and Ph.D. degrees from Yale University. ANNEX B ATTACHMENT 2 INFORMATION ABOUT NOMINEES -------------------------- NAME: Richard C. Mulligan, Ph.D AGE: 56 BUSINESS Harvard Institutes of Medicine, Rm 407 ADDRESS: 4 Blackfan Circle Boston, MA 02115 RESIDENCE 35 Foster Street ADDRESS: Cambridge, MA 02138 PRINCIPAL OCCUPATION See below OR EMPLOYMENT: CITIZENSHIP: United States of America Dr. Mulligan does not, and his associates do not, own, beneficially or of record, any shares of capital stock of the Corporation. Dr. Mulligan has an interest in the election of directors at the Annual Meeting pursuant to the Nominee Agreement attached hereto as Annex D. Dr. Mulligan's principal occupation is serving as the Mallinckrodt Professor of Genetics at Harvard Medical School, and Director of the Harvard Gene Therapy Initiative. Professor Mulligan received his B.S. degree from the Massachusetts Institute of Technology, and his Ph.D. from the Department of Biochemistry at Stanford University School of Medicine. After receiving postdoctoral training at the Center for Cancer Research at MIT, Professor Mulligan joined the MIT faculty and subsequently was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Children's Hospital and Harvard in 1996. His honors include the MacArthur Foundation Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award, and the Nagai Foundation International Prize. Dr. Mulligan served as a director of ImClone System Incorporated, a publicly traded biopharmaceutical company, from September 2006 until November 2008, and as a member of Scientific Advisory Board and Executive Committee. In addition, Dr. Mulligan has served as a director of Biogen Idec Pharmaceuticals, a publicly traded biopharmaceutical company from June 2009 until the present, as a director of Enzon Pharmaceuticals, a publicly traded biopharmaceutical company from May 2009 until the present, and as a director of Cellectis SA, a biotechnology company which specializes in genome engineering, since 2007. He has also served on the National Institutes of Health's Recombinant DNA Advisory Committee and on the U.S. Food and Drug Administration Biological Response Modifiers Advisory Committee. ANNEX B ATTACHMENT 3 INFORMATION ABOUT NOMINEES -------------------------- NAME: Professor Lucian Bebchuk AGE: 55 BUSINESS 22 Sacramento Street ADDRESS: Cambridge, MA 02138 RESIDENCE 1545 Massachusetts Avenue ADDRESS: Cambridge, MA 02138 PRINCIPAL OCCUPATION See below OR EMPLOYMENT: CITIZENSHIP: United States of America Professor Bebchuk does not, and his associates do not, own, beneficially or of record, any shares of capital stock of the Corporation. Professor Bebchuk has an interest in the election of directors at the Annual Meeting pursuant to the Nominee Agreement attached hereto as Annex D. Professor Bebchuk's principal occupation is serving as the William J. Friedman and Alicia Townsend Friedman Professor of Law, Economics, and Finance and Director of the Program on Corporate Governance at Harvard Law School. Professor Bebchuk is also a Research Associate of the National Bureau of Economic Research and Inaugural Fellow of the European Corporate Governance Network. Trained in both law and economics, Professor Bebchuk holds an LL.M. and S.J.D. from Harvard Law School and an M.A. and a Ph.D. in Economics from the Harvard Economics Department. His research focuses on corporate governance, law and finance, and law and economics. Upon electing him to membership in 2000, the American Academy of Arts and Sciences cited him as "[o]ne of the nation's leading scholars of law and economics," who "has made major contribution to the study of corporate control, governance, and insolvency." The author of more than one hundred research papers, Professor Bebchuk's work has appeared in the top academic journals in law, in economics, and in finance. His widely acclaimed book, Pay without Performance: the Unfulfilled Promise of Executive Compensation, co-authored with Jesse Fried, was published in 2004. Professor Bebchuk has been a frequent contributor to policy-making, practice, and public debate in the fields of corporate governance and financial regulation. He has appeared in hearings and roundtables before the Senate Finance Committee, the House of Representatives Committee of Financial Services, and the SEC; has advised publicly traded firms, governmental authorities both in and outside the U.S., and law firms; has authored numerous op-ed pieces, including in the Wall Street Journal, the New York Times, and the Financial Times; and serves on the board of directors of OJSC MMC Norilsk Nickel, the world's largest producer of nickel and palladium. He was included in the list of "100 most influential players in corporate governance" of Directorship, the "100 most influential people in finance" of Treasury & Risk Management, and the list of top-10 "governance stars" of Global Proxy Watch. Professor Bebchuk served as President of the American Law and Economics Association and Chair of the Business Association Section of the American Association of Law Teachers. He is a Vice-President of the Western Economics Association International and the founding Director of the SSRN Corporate Governance Network. ANNEX B ATTACHMENT 4 INFORMATION ABOUT NOMINEES -------------------------- NAME: Eric J. Ende, M.D. AGE: 43 BUSINESS 6231 PGA Blvd, STE 104-161 ADDRESS: Palm Beach Gardens, FL 33418 RESIDENCE 102 Via Palacio ADDRESS: Palm Beach Gardens, FL 33418 PRINCIPAL OCCUPATION See below OR EMPLOYMENT: CITIZENSHIP: United States of America Dr. Ende does not, and his associates do not, own, beneficially or of record, any shares of capital stock of the Corporation. Dr. Ende has an interest in the election of directors at the Annual Meeting pursuant to the Nominee Agreement attached hereto as Annex D. Dr. Ende's principal occupation is serving as President of Ende Consulting Group, which is focused on biotechnology industry consulting, since 2009. Since 2008, Dr. Ende has also served as a Managing Partner of Silverback Group, which is focused on identifying, evaluating and participating in various types of investment opportunities, including venture capital, real estate and financings. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 to 2002, he was the senior biotechnology analyst at Banc of America Securities. From 1997 to 2000, he was a biotechnology analyst at Lehman Brothers. During Dr. Ende's career as a biotechnology analyst, he was named to Institutional Investor's AllAmerica Equity Research Team six times as well as to The Greenwich Survey list of top analysts. He was also named Top Stock Picker by The Street.com and Best Earnings Estimator by Forbes.com. Dr. Ende served as a director of Genzyme Corporation from 2010 until it was acquired by Sanofi-Aventis in 2011. Dr. Ende received an M.B.A. in Finance & Accounting from New York University's Stern Business School in 1997, an M.D. from Mount Sinai School of Medicine in 1994, and a B.S. in Biology and Psychology from Emory University in 1990. ANNEX C The written consent of each Nominee to, among other things, being named as a nominee for election as a director of the Corporation and to serve as a director if elected is attached to this Annex C. If the Corporation requests original signed statements of consents, the Record Holder will provide them. ANNEX C ATTACHMENT 1 CONSENT OF NOMINEE The undersigned hereby consents to being named as a nominee for election as a director of Forest Laboratories, Inc. (the "Company"), in the proxy statement to be filed with the Securities and Exchange Commission and distributed to stockholders of the Company by High River Limited Partnership ("High River"), Icahn Partners LP ("Icahn Partners"), Icahn Partners Master Fund LP ("Icahn Master"), Icahn Partners Master Fund II LP ("Icahn Master II"), Icahn Partners Master Fund III LP ("Icahn Master III", and collectively with High River, Icahn Partners, Icahn Master and Icahn Master II, the "Holders") and in other materials in connection with the solicitation of proxies by the Holders from stockholders of the Company to be voted at the 2011 annual meeting of stockholders of the Company and any adjournment thereof, and further consents to serve as a director of the Company, if elected. The undersigned hereby consents to the disclosure of all information relating to the undersigned as would be required to be disclosed in solicitations of proxies for the election of the undersigned as a director pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, in any such solicitation made by the Company. The undersigned, if elected, intends to tender, promptly following the undersigned's election or reelection, an irrevocable resignation effective upon the undersigned's failure to receive the required vote for reelection at the next meeting at which the undersigned would face reelection and upon acceptance of such resignation by the board of directors, in accordance with the Company's Board Practice on Director Elections. Dated: June 9, 2011 /s/ Alexander J. Denner ------------------------- Name: Alexander J. Denner ANNEX C ATTACHMENT 2 CONSENT OF NOMINEE The undersigned hereby consents to being named as a nominee for election as a director of Forest Laboratories, Inc. (the "Company"), in the proxy statement to be filed with the Securities and Exchange Commission and distributed to stockholders of the Company by High River Limited Partnership ("High River"), Icahn Partners LP ("Icahn Partners"), Icahn Partners Master Fund LP ("Icahn Master"), Icahn Partners Master Fund II LP ("Icahn Master II"), Icahn Partners Master Fund III LP ("Icahn Master III", and collectively with High River, Icahn Partners, Icahn Master and Icahn Master II, the "Holders") and in other materials in connection with the solicitation of proxies by the Holders from stockholders of the Company to be voted at the 2011 annual meeting of stockholders of the Company and any adjournment thereof, and further consents to serve as a director of the Company, if elected. The undersigned hereby consents to the disclosure of all information relating to the undersigned as would be required to be disclosed in solicitations of proxies for the election of the undersigned as a director pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, in any such solicitation made by the Company. The undersigned, if elected, intends to tender, promptly following the undersigned's election or reelection, an irrevocable resignation effective upon the undersigned's failure to receive the required vote for reelection at the next meeting at which the undersigned would face reelection and upon acceptance of such resignation by the board of directors, in accordance with the Company's Board Practice on Director Elections. Dated: June 8, 2011 /s/ Richard Mulligan --------------------- Name: Richard Mulligan ANNEX C ATTACHMENT 3 CONSENT OF NOMINEE The undersigned hereby consents to being named as a nominee for election as a director of Forest Laboratories, Inc. (the "Company"), in the proxy statement to be filed with the Securities and Exchange Commission and distributed to stockholders of the Company by High River Limited Partnership ("High River"), Icahn Partners LP ("Icahn Partners"), Icahn Partners Master Fund LP ("Icahn Master"), Icahn Partners Master Fund II LP ("Icahn Master II"), Icahn Partners Master Fund III LP ("Icahn Master III", and collectively with High River, Icahn Partners, Icahn Master and Icahn Master II, the "Holders") and in other materials in connection with the solicitation of proxies by the Holders from stockholders of the Company to be voted at the 2011 annual meeting of stockholders of the Company and any adjournment thereof, and further consents to serve as a director of the Company, if elected. The undersigned hereby consents to the disclosure of all information relating to the undersigned as would be required to be disclosed in solicitations of proxies for the election of the undersigned as a director pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, in any such solicitation made by the Company. The undersigned, if elected, intends to tender, promptly following the undersigned's election or reelection, an irrevocable resignation effective upon the undersigned's failure to receive the required vote for reelection at the next meeting at which the undersigned would face reelection and upon acceptance of such resignation by the board of directors, in accordance with the Company's Board Practice on Director Elections. Dated: June 9, 2011 /s/ Lucian A. Bebchuk ----------------------- Name: Lucian A. Bebchuk ANNEX C ATTACHMENT 4 CONSENT OF NOMINEE The undersigned hereby consents to being named as a nominee for election as a director of Forest Laboratories, Inc. (the "Company"), in the proxy statement to be filed with the Securities and Exchange Commission and distributed to stockholders of the Company by High River Limited Partnership ("High River"), Icahn Partners LP ("Icahn Partners"), Icahn Partners Master Fund LP ("Icahn Master"), Icahn Partners Master Fund II LP ("Icahn Master II"), Icahn Partners Master Fund III LP ("Icahn Master III", and collectively with High River, Icahn Partners, Icahn Master and Icahn Master II, the "Holders") and in other materials in connection with the solicitation of proxies by the Holders from stockholders of the Company to be voted at the 2011 annual meeting of stockholders of the Company and any adjournment thereof, and further consents to serve as a director of the Company, if elected. The undersigned hereby consents to the disclosure of all information relating to the undersigned as would be required to be disclosed in solicitations of proxies for the election of the undersigned as a director pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, in any such solicitation made by the Company. The undersigned, if elected, intends to tender, promptly following the undersigned's election or reelection, an irrevocable resignation effective upon the undersigned's failure to receive the required vote for reelection at the next meeting at which the undersigned would face reelection and upon acceptance of such resignation by the board of directors, in accordance with the Company's Board Practice on Director Elections. Dated: June 8, 2011 /s/ Eric Ende -------------- Name: Eric Ende ANNEX D Attached to this Annex D is the form of agreement to be entered into by the Nominees (other than Dr. Denner) and an affiliate of the Record Holder pursuant to which such affiliate has agreed to pay certain fees to such Nominees and to indemnify such Nominees with respect to certain costs incurred by such Nominees in connection with the proxy contest relating to the Annual Meeting. ICAHN CAPITAL LP June 9, 2011 To the undersigned potential nominee: This will confirm our understanding as follows: You agree that you are willing, should we so elect, to become a member of a slate of nominees (the "Slate") to stand for election as directors of Forest Laboratories, Inc. ("Forest Laboratories") in connection with a proxy contest with management of Forest Laboratories in respect of the election of directors of Forest Laboratories at the 2011 Annual Meeting of Shareholders of Forest Laboratories (the "Annual Meeting"), expected to be held in the Summer of 2011, or a special meeting of shareholders of Forest Laboratories called for a similar purpose (the "Proxy Contest"). Icahn Capital LP ("Icahn") agrees to pay the costs of the Proxy Contest. In addition, upon our filing of a preliminary proxy statement with the SEC, which indicates that Icahn, or an affiliate thereof, intends to nominate you for election at the Annual Meeting, you will be entitled to be paid $25,000 by Icahn unless you are elected to serve as a director of Forest Laboratories at the Annual Meeting or a special meeting of shareholders of Forest Laboratories called for a similar purpose or in connection with a settlement of the Proxy Contest by Icahn and Forest Laboratories, in which case you will not receive any payment from Icahn in connection with the Proxy Contest. Payment to you pursuant to this paragraph, if any, will be made by Icahn, subject to the terms hereof, upon the earliest of (i) the certification of the results of the election in respect of the Proxy Contest, (ii) the settlement of the Proxy Contest by Icahn and Forest Laboratories, or (iii) the withdrawal of the Proxy Contest by Icahn. You understand that it may be difficult, if not impossible, to replace nominees who, such as yourself, have agreed to serve on the Slate and later change their minds and determine not to seek election. Accordingly, the Slate is relying upon your agreement to seek election. In that connection, you are being supplied with a questionnaire in which you will provide Icahn with information necessary for Icahn to make appropriate disclosure both to Forest Laboratories and for use in creating the proxy material to be sent to shareholders of Forest Laboratories and to be filed with the Securities and Exchange Commission. You have agreed that (i) you will immediately complete and sign the questionnaire and return it to Mark DiPaolo, Assistant General Counsel, Icahn Enterprises LP, 767 Fifth Avenue, Suite 4700, New York, NY 10153, Tel: (212) 702-4361, Fax: (212) 688-1158, Email: mdipaolo@sfire.com and (ii) your responses to the questions contained therein will be true and correct in all respects. In addition, you have agreed that, concurrently with your execution of this letter, you will execute the attached instrument directed to Forest Laboratories informing Forest Laboratories that you consent to being nominated by Icahn, or an affiliate thereof, for election as a director of Forest Laboratories and, if elected, consent to serving as a director of Forest Laboratories and consent to the disclosure of certain information relating to you as would be required to be disclosed in solicitations of proxies for your election as a director pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, in any such solicitation made by the Company. You also will make a statement in the attached instrument that if elected, you intend to tender, promptly following your election or reelection, an irrevocable resignation effective upon your failure to receive the required vote for reelection at the next meeting at which you would face reelection and upon acceptance of such resignation by the board of directors, in accordance with the Company's Board Practice on Director Elections. Upon being notified that we have chosen you, we may forward that instrument and your completed questionnaire (or summaries thereof) to Forest Laboratories. Icahn hereby agrees that, so long as you actually serve on the Slate, Icahn will defend, indemnify and hold you harmless from and against any and all losses, damages, penalties, judgments, awards, liabilities, costs, expenses and disbursements (including, without limitation, reasonable attorneys' fees, costs, expenses and disbursements) incurred by you in the event that (i) you become a party, or are threatened to be made a party, to any civil, criminal, administrative or arbitrative action, suit or proceeding, and any appeal thereof relating solely to your role as a nominee for director of Forest Laboratories on the Slate (a "Proceeding") or (ii) you are called to testify or give a deposition in any Proceeding (whether or not you are a party or are threatened to be made a party to such Proceeding), including, in each case, the advancement to you of all reasonable attorneys' costs and expenses incurred by you in connection with any Proceeding. Your right of indemnification hereunder shall continue (i) in the event that Icahn determines to withdraw the Slate or remove you from the Slate and (ii) after the election has taken place but only for events which occur prior to such election and subsequent to the date hereof. Anything to the contrary herein notwithstanding, Icahn is not indemnifying you for any action taken by you or on your behalf which occurs prior to the date hereof or subsequent to the Annual Meeting or such earlier time as you are no longer a nominee of the Slate for election to Forest Laboratories' Board of Directors or for any actions taken by you as a director of Forest Laboratories, if you are elected. Nothing herein shall be construed to provide you an indemnity: (i) in the event you are found to have engaged in a violation of any provision of state or federal law in connection with the Proxy Contest unless you demonstrate that your action was taken in good faith and in a manner you reasonably believed to be in or not opposed to the best interests of electing the Slate; or (ii) if you acted in a manner which constitutes gross negligence or willful misconduct. In the event that you shall make any claim for indemnification hereunder, you shall promptly notify Icahn in the event of any third-party claims actually made against you or known by you to be threatened. In addition, with respect to any such claim, Icahn shall be entitled to control your defense with counsel chosen by Icahn. Icahn shall not be responsible for any settlement of any claim against you covered by this indemnity without its prior written consent. However, Icahn may not enter into any settlement of any such claim without your consent unless such settlement includes a release of you from any and all liability in respect of such claim. Each of us recognizes that should you be elected to the Board of Directors of Forest Laboratories all of your activities and decisions as a director will be governed by applicable law and subject to your fiduciary duty to the stockholders of Forest Laboratories and, as a result, that there is, and can be, no agreement between you and Icahn which governs the decisions which you will make as a director of Forest Laboratories. Should the foregoing agree with your understanding, please so indicate in the space provided below, whereupon this letter will become a binding agreement between us. Very truly yours, ICAHN CAPITAL LP By: __________________________ Name: Edward E. Mattner Title: Authorized Signatory Agreed to and Accepted as of the date first above written: __________________________ Name: